OBJECTIVES: This trial was designed and patients were recruited at a time when the benefits of remote ischaemic preconditioning during open-heart surgery were still controversial. We focused on a homogeneous patient population undergoing either isolated aortic valve replacement or coronary artery bypass grafting (CABG) surgery by investigating cardiac injury, metabolic stress and inflammatory response. METHODS: A 2-centre randomized controlled trial recruited a total of 124 patients between February 2013 and April 2015. Of them, 64 patients underwent CABG and 60 patients underwent aortic valve replacement. Patients were randomized to either sham or preconditioning. Remote ischaemic preconditioning was applied following anaesthesia and before sternotomy. Myocardial injury and inflammatory response were assessed by serially measuring cardiac troponin I, and interleukin-6, 8, 10 and the tumour necrosis factor (TNF-α). Biopsies from the left and the right ventricles were harvested after ischaemic reperfusion injury for nucleotides analysis. RESULTS: Application of remote ischaemic preconditioning did not alter the degree of troponin I release, levels of inflammatory markers and cardiac energetics in both the CABG and the aortic valve replacement groups. CONCLUSIONS: Preconditioning did not confer any additional cardioprotection in terms of reducing the levels of troponin I and inflammatory markers and preserving left and right ventricle energy metabolites in patients undergoing isolated CABG or aortic valve surgery. CLINICAL TRIAL REGISTRATION NUMBER: International Standard Randomized Controlled Trial Number (ISRCTN) registry ID 33084113 (doi: 10.1186/ISRCTN33084113) and UK controlled randomized trial number (UKCRN) registry ID 13672.
OBJECTIVES: This trial was designed and patients were recruited at a time when the benefits of remote ischaemic preconditioning during open-heart surgery were still controversial. We focused on a homogeneous patient population undergoing either isolated aortic valve replacement or coronary artery bypass grafting (CABG) surgery by investigating cardiac injury, metabolic stress and inflammatory response. METHODS: A 2-centre randomized controlled trial recruited a total of 124 patients between February 2013 and April 2015. Of them, 64 patients underwent CABG and 60 patients underwent aortic valve replacement. Patients were randomized to either sham or preconditioning. Remote ischaemic preconditioning was applied following anaesthesia and before sternotomy. Myocardial injury and inflammatory response were assessed by serially measuring cardiac troponin I, and interleukin-6, 8, 10 and the tumour necrosis factor (TNF-α). Biopsies from the left and the right ventricles were harvested after ischaemic reperfusion injury for nucleotides analysis. RESULTS: Application of remote ischaemic preconditioning did not alter the degree of troponin I release, levels of inflammatory markers and cardiac energetics in both the CABG and the aortic valve replacement groups. CONCLUSIONS: Preconditioning did not confer any additional cardioprotection in terms of reducing the levels of troponin I and inflammatory markers and preserving left and right ventricle energy metabolites in patients undergoing isolated CABG or aortic valve surgery. CLINICAL TRIAL REGISTRATION NUMBER: International Standard Randomized Controlled Trial Number (ISRCTN) registry ID 33084113 (doi: 10.1186/ISRCTN33084113) and UK controlled randomized trial number (UKCRN) registry ID 13672.
Authors: Eliana Lucchinetti; Lukas Bestmann; Jianhua Feng; Heike Freidank; Alexander S Clanachan; Barry A Finegan; Michael Zaugg Journal: Anesthesiology Date: 2012-02 Impact factor: 7.892
Authors: Patrick Meybohm; Berthold Bein; Oana Brosteanu; Jochen Cremer; Matthias Gruenewald; Christian Stoppe; Mark Coburn; Gereon Schaelte; Andreas Böning; Bernd Niemann; Jan Roesner; Frank Kletzin; Ulrich Strouhal; Christian Reyher; Rita Laufenberg-Feldmann; Marion Ferner; Ivo F Brandes; Martin Bauer; Sebastian N Stehr; Andreas Kortgen; Maria Wittmann; Georg Baumgarten; Tanja Meyer-Treschan; Peter Kienbaum; Matthias Heringlake; Julika Schön; Michael Sander; Sascha Treskatsch; Thorsten Smul; Ewa Wolwender; Thomas Schilling; Georg Fuernau; Dirk Hasenclever; Kai Zacharowski Journal: N Engl J Med Date: 2015-10-05 Impact factor: 91.245
Authors: Derek J Hausenloy; Luciano Candilio; Richard Evans; Cono Ariti; David P Jenkins; Shyam Kolvekar; Rosemary Knight; Gudrun Kunst; Christopher Laing; Jennifer Nicholas; John Pepper; Steven Robertson; Maria Xenou; Tim Clayton; Derek M Yellon Journal: N Engl J Med Date: 2015-10-05 Impact factor: 91.245
Authors: Francesca Fiorentino; Gianni D Angelini; M-Saadeh Suleiman; Alima Rahman; Jon Anderson; Alan J Bryan; Lucy A Culliford; Marco Moscarelli; Prakash P Punjabi; Barnaby C Reeves Journal: Trials Date: 2015-04-23 Impact factor: 2.279
Authors: Safa Abdul-Ghani; Katie L Skeffington; Minjoo Kim; Marco Moscarelli; Philip A Lewis; Kate Heesom; Francesca Fiorentino; Costanza Emanueli; Barnaby C Reeves; Prakash P Punjabi; Gianni D Angelini; M-Saadeh Suleiman Journal: Int J Mol Med Date: 2022-04-15 Impact factor: 5.314
Authors: Katie L Skeffington; Marco Moscarelli; Safa Abdul-Ghani; Francesca Fiorentino; Costanza Emanueli; Barnaby C Reeves; Prakash P Punjabi; Gianni D Angelini; M-Saadeh Suleiman Journal: Front Cardiovasc Med Date: 2022-07-22